M Lang1, T Leménager2, F Streit3, M Fauth-Bühler2, J Frank3, D Juraeva4, S H Witt3, F Degenhardt5, A Hofmann5, S Heilmann-Heimbach5, F Kiefer2, B Brors4, H-J Grabe6, U John7, A Bischof8, G Bischof8, U Völker9, G Homuth10, M Beutel11, P A Lind12, S E Medland12, W S Slutske13, N G Martin14, H Völzke15, M M Nöthen5, C Meyer7, H-J Rumpf8, F M Wurst16, M Rietschel3, K F Mann2. 1. Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty, Mannheim/Heidelberg University, Mannheim, Germany. Electronic address: Maren.Lang@zi-mannheim.de. 2. Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty, Mannheim/Heidelberg University, Mannheim, Germany. 3. Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty, Mannheim/Heidelberg University, Mannheim, Germany. 4. Division of Applied Bioinformatics, German Cancer Research Center, Heidelberg, Germany. 5. Institute of Human Genetics, University of Bonn, Bonn, Germany; Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. 6. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Helios Hospital Stralsund, Stralsund, Germany; German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Germany. 7. Department of Social Medicine and Prevention, University Medicine Greifswald, Greifswald, Germany; Partner site Greifswald, (DZHK) German Centre for Cardiovascular Research, Greifswald, Germany. 8. Department of Psychiatry and Psychotherapy, University of Luebeck, Luebeck, Germany. 9. Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany; Partner site Greifswald, (DZHK) German Centre for Cardiovascular Research, Greifswald, Germany. 10. Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany. 11. Kraichtal-Kliniken, Kraichtal, Germany. 12. Department of Quantitative Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. 13. Department of Psychological Sciences, University of Missouri, Columbia, MO, USA. 14. Department of Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. 15. Institute for Community Medicine, University of Greifswald, Center for Dental, Oral and Maxillofacial Medicine, University of Greifswald, Institute of Social Medicine and Prevention, University of Greifswald, Greifswald, Germany; Partner site Greifswald, (DZHK) German Centre for Cardiovascular Research, Greifswald, Germany. 16. Centre for Interdisciplinary Addiction Research (CIAR), University of Hamburg, Hamburg, Germany; Paracelsus Medical University, Salzburg, Austria.
Abstract
BACKGROUND: Pathological gambling is a behavioural addiction with negative economic, social, and psychological consequences. Identification of contributing genes and pathways may improve understanding of aetiology and facilitate therapy and prevention. Here, we report the first genome-wide association study of pathological gambling. Our aims were to identify pathways involved in pathological gambling, and examine whether there is a genetic overlap between pathological gambling and alcohol dependence. METHODS: Four hundred and forty-five individuals with a diagnosis of pathological gambling according to the Diagnostic and Statistical Manual of Mental Disorders were recruited in Germany, and 986 controls were drawn from a German general population sample. A genome-wide association study of pathological gambling comprising single marker, gene-based, and pathway analyses, was performed. Polygenic risk scores were generated using data from a German genome-wide association study of alcohol dependence. RESULTS: No genome-wide significant association with pathological gambling was found for single markers or genes. Pathways for Huntington's disease (P-value=6.63×10(-3)); 5'-adenosine monophosphate-activated protein kinase signalling (P-value=9.57×10(-3)); and apoptosis (P-value=1.75×10(-2)) were significant. Polygenic risk score analysis of the alcohol dependence dataset yielded a one-sided nominal significant P-value in subjects with pathological gambling, irrespective of comorbid alcohol dependence status. CONCLUSIONS: The present results accord with previous quantitative formal genetic studies which showed genetic overlap between non-substance- and substance-related addictions. Furthermore, pathway analysis suggests shared pathology between Huntington's disease and pathological gambling. This finding is consistent with previous imaging studies.
BACKGROUND: Pathological gambling is a behavioural addiction with negative economic, social, and psychological consequences. Identification of contributing genes and pathways may improve understanding of aetiology and facilitate therapy and prevention. Here, we report the first genome-wide association study of pathological gambling. Our aims were to identify pathways involved in pathological gambling, and examine whether there is a genetic overlap between pathological gambling and alcohol dependence. METHODS: Four hundred and forty-five individuals with a diagnosis of pathological gambling according to the Diagnostic and Statistical Manual of Mental Disorders were recruited in Germany, and 986 controls were drawn from a German general population sample. A genome-wide association study of pathological gambling comprising single marker, gene-based, and pathway analyses, was performed. Polygenic risk scores were generated using data from a German genome-wide association study of alcohol dependence. RESULTS: No genome-wide significant association with pathological gambling was found for single markers or genes. Pathways for Huntington's disease (P-value=6.63×10(-3)); 5'-adenosine monophosphate-activated protein kinase signalling (P-value=9.57×10(-3)); and apoptosis (P-value=1.75×10(-2)) were significant. Polygenic risk score analysis of the alcohol dependence dataset yielded a one-sided nominal significant P-value in subjects with pathological gambling, irrespective of comorbid alcohol dependence status. CONCLUSIONS: The present results accord with previous quantitative formal genetic studies which showed genetic overlap between non-substance- and substance-related addictions. Furthermore, pathway analysis suggests shared pathology between Huntington's disease and pathological gambling. This finding is consistent with previous imaging studies.
Authors: Spencer B Huggett; Evan A Winiger; Robin P Corley; John K Hewitt; Michael C Stallings Journal: Addict Behav Date: 2019-01-21 Impact factor: 3.913
Authors: Christal N Davis; Wendy S Slutske; Nicholas G Martin; Arpana Agrawal; Michael T Lynskey Journal: Psychol Med Date: 2018-08-30 Impact factor: 7.723
Authors: Susana Jiménez-Murcia; Roser Granero; Ines Wolz; Marta Baño; Gemma Mestre-Bach; Trevor Steward; Zaida Agüera; Anke Hinney; Carlos Diéguez; Felipe F Casanueva; Ashley N Gearhardt; Anders Hakansson; José M Menchón; Fernando Fernández-Aranda Journal: Front Psychol Date: 2017-04-04
Authors: Claire L Dent; Trevor Humby; Katie Lewis; Andrew Ward; Reiner Fischer-Colbrie; Lawrence S Wilkinson; Jon F Wilkins; Anthony R Isles Journal: Genetics Date: 2018-03-21 Impact factor: 4.562
Authors: Kellyn M Spychala; Ian R Gizer; Christal N Davis; Genevieve F Dash; Thomas M Piasecki; Wendy S Slutske Journal: Addiction Date: 2021-09-08 Impact factor: 7.256
Authors: Kenneth Blum; Shan Kazmi; Edward J Modestino; Bill William Downs; Debasis Bagchi; David Baron; Thomas McLaughlin; Richard Green; Rehan Jalali; Panayotis K Thanos; Igor Elman; Rajendra D Badgaiyan; Abdalla Bowirrat; Mark S Gold Journal: J Pers Med Date: 2021-03-16